摘要
目的:探讨急性早幼粒细胞白血病(APL)PML-RARα融合基因异构体及其临床关系。方法:用逆转录/聚合酶链反应(RT/PCR)检测21例初诊APL患者细胞中PML-RARα融合基因转录本,并分析其对临床特征的可能不同影响。结果:在ATRA诱导治疗过程中,短型PML-RARα异构体APL组的早期死亡和复发率(4/8)(50%)高于长型PML-RARα异构体组(2/13)(15.4%);与长型异构体相反,存活期2月至2年患者含短型异构体的比例(75%)大于存活期2年以上组(33.3%);未观察到患者血液学参数改变与不同PML-RARα异构体有关。结论:与长型PML-RARα异构体组APL患者相比,短型PML-RARα异构体组的预后可能更差。
Objective:To illustrate the clinical relevance of distinct PML RARα fusion gene isoforms in acute promyelocytic leukemia(APL).Methods:The retrotranscriptase/polymerase chain reaction(RT/PCR) was used to evaluate the clinical relevance of the long (L) or short (S) PML RARα fusion mRNA isoforms in 21 initial patients with APL.Results:There were more early deaths during the all transretinoic acid(ATRA) induction treatment and more relapses within 2 years of complete remission (CR) in the S type (4 of 8 case) than that in the L type group (2 of 13).Compared with L type isoforms,the ratio of S type was more in patients survived 2 months through 2 years than those survived beyond 2 years (75% Vs 33.3%). It was not found that relations between hematological parameters and PML RARα isoforms.And PML RARα isoforms were remained negative test in 4 cases of CR 3 years more.Conclusion:The S type PML RARα isoforms may be involved much poor prognosis than L type PML RARα isofoms in APL.
出处
《华夏医学》
1999年第4期16-18,共3页
Acta Medicinae Sinica
基金
广西壮族自治区卫生厅资助